RecruitingPhase 4NCT06274515

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

A Multi Cohort Translational Research Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

Sponsor

Hoffmann-La Roche

Enrollment

320 participants

Start Date

Apr 2, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is trying to understand why some breast cancer treatments stop working over time. Researchers will collect tumor tissue samples (via biopsy) and blood from patients whose cancer has started growing again despite treatment, to study what changes in the tumor caused it to become resistant. **You may be eligible if...** - You have been diagnosed with HER2-positive, hormone receptor-positive, or triple-negative breast cancer - Your cancer has started growing again (progressing) despite treatment - You stopped your last cancer treatment no more than 4 weeks ago - You have a tumor that can be safely biopsied or removed - You are willing to have a biopsy and a blood draw **You may NOT be eligible if...** - You have a bleeding disorder or other condition that makes biopsy risky - You have already started a new cancer treatment - The growing tumor being targeted is in the bone - You have serious health conditions that would make participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURETumor Tissue and Blood Draw

Participants will have their blood drawn on the day a tissue sample is taken from a progressive tumor lesion.

Locations(28)

Institut Jules Bordet

Anderlecht, Belgium

AZ KLINA

Brasschaat, Belgium

CHU de Liège (Sart Tilman)

Liège, Belgium

AZ Delta (Campus Rumbeke)

Roeselare, Belgium

Aalborg Universitetshospital

Aalborg, Denmark

Sjællands Universitetshospital, Næstved

Næstved, Denmark

Helsinki University Central Hospital

Helsinki, Finland

Tampere University Hospital

Tampere, Finland

St. Elisabeth Krankenhaus Köln GmbH

Cologne, Germany

KEM/Evang. Kliniken Essen Mitte gGmbH

Essen, Germany

ViDia Christliche Kliniken Karlsruhe, Vincentius-Diakonissen-Kliniken gAG

Karlsruhe, Germany

Universitätsklinikum Mannheim

Mannheim, Germany

Universitätsfrauenklinik Ulm

Ulm, Germany

I.R.S.T Srl IRCCS

Meldola, Emilia-Romagna, Italy

Azienda Ospedaliero - Universitaria di Modena Policlinico

Modena, Emilia-Romagna, Italy

RCCS - Centro di Riferimento

Aviano (PN), Friuli Venezia Giulia, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Lazio, Italy

Ospedale San Raffaele S.r.l. - PPDS

Milan, Lombardy, Italy

Irccs Istituto Nazionale Dei Tumori (Int)

Milan, Lombardy, Italy

Irccs Istituto Europeo Di Oncologia (IEO)

Milan, Lombardy, Italy

Oslo university hospital Radiumhospitalet

Oslo, Norway

Hospital Universitario 12 de Octubre

Madrid, Spain

HM Sanchinarro ? CIOCC

Madrid, Spain

Hospital Universitario Virgen del Rocio

Seville, Spain

Hospital Clínico Universitario de Valencia

Valencia, Spain

Basingstoke and North Hampshire Hospital

Basingstoke, United Kingdom

Imperial College Healthcare NHS Trust

London, United Kingdom

Christie Hospital NHS Trust

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06274515

Related Trials

Genomic Services Research Program

NCT025959571 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations

Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity

NCT070707652 locations

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations